99 related articles for article (PubMed ID: 12457287)
1. Encapsulation of recombinant adenovirus into alginate microspheres circumvents vector-specific immune response.
Sailaja G; HogenEsch H; North A; Hays J; Mittal SK
Gene Ther; 2002 Dec; 9(24):1722-9. PubMed ID: 12457287
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity and protective efficacy of a recombinant adenovirus containing the fusion protein of bovine parainfluenza virus type 3 genotype C in mice.
Zhang J; Zeng J; Yuan Z; Huang X; Wu J; Yu Q; Chen T; Den G; Zhu C; Zhang B
Microb Pathog; 2023 Dec; 185():106444. PubMed ID: 37951410
[TBL] [Abstract][Full Text] [Related]
3. An intranasal combination vaccine induces systemic and mucosal immunity against COVID-19 and influenza.
Xing M; Hu G; Wang X; Wang Y; He F; Dai W; Wang X; Niu Y; Liu J; Liu H; Zhang X; Xu J; Cai Q; Zhou D
NPJ Vaccines; 2024 Mar; 9(1):64. PubMed ID: 38509167
[TBL] [Abstract][Full Text] [Related]
4. Manganese Mineralization of Pathogenic Viruses as a Universal Vaccine Platform.
Shi PD; Xu YP; Zhu Z; Zhou C; Wu M; He Y; Zhao H; Liu L; Zhao L; Li XF; Qin CF
Adv Sci (Weinh); 2023 Nov; 10(33):e2303615. PubMed ID: 37867242
[TBL] [Abstract][Full Text] [Related]
5. Adenoviral Vector-Based Vaccine Platform for COVID-19: Current Status.
Chavda VP; Bezbaruah R; Valu D; Patel B; Kumar A; Prasad S; Kakoti BB; Kaushik A; Jesawadawala M
Vaccines (Basel); 2023 Feb; 11(2):. PubMed ID: 36851309
[TBL] [Abstract][Full Text] [Related]
6. Significance of Preexisting Vector Immunity and Activation of Innate Responses for Adenoviral Vector-Based Therapy.
Wang WC; Sayedahmed EE; Mittal SK
Viruses; 2022 Dec; 14(12):. PubMed ID: 36560730
[TBL] [Abstract][Full Text] [Related]
7. rAAV expressing recombinant neutralizing antibody for the botulinum neurotoxin type A prophylaxis.
Derkaev AA; Ryabova EI; Esmagambetov IB; Shcheblyakov DV; Godakova SA; Vinogradova ID; Noskov AN; Logunov DY; Naroditsky BS; Gintsburg AL
Front Microbiol; 2022; 13():960937. PubMed ID: 36238585
[TBL] [Abstract][Full Text] [Related]
8. The use of adenoviral vectors in gene therapy and vaccine approaches.
Araújo NM; Rubio IGS; Toneto NPA; Morale MG; Tamura RE
Genet Mol Biol; 2022; 45(3 Suppl 1):e20220079. PubMed ID: 36206378
[TBL] [Abstract][Full Text] [Related]
9. Prolongation of Fate of Bacteriophages In Vivo by Polylactic-Co-Glycolic-Acid/Alginate-Composite Encapsulation.
Kim SG; Giri SS; Jo SJ; Kang JW; Lee SB; Jung WJ; Lee YM; Kim HJ; Kim JH; Park SC
Antibiotics (Basel); 2022 Sep; 11(9):. PubMed ID: 36140043
[TBL] [Abstract][Full Text] [Related]
10. Microencapsulated Multifunctionalized Graphene Oxide Equipped with Chloroquine for Efficient and Sustained siRNA Delivery.
Imani R; Prakash S; Vali H; Presley JF; Faghihi S
Biomed Res Int; 2022; 2022():5866361. PubMed ID: 35469347
[TBL] [Abstract][Full Text] [Related]
11. COVID-19 Vaccines: An Overview of Different Platforms.
Kudlay D; Svistunov A
Bioengineering (Basel); 2022 Feb; 9(2):. PubMed ID: 35200425
[TBL] [Abstract][Full Text] [Related]
12. Human Adenovirus Serotype 3 Infection Modulates the Biogenesis and Composition of Lung Cell-Derived Extracellular Vesicles.
Ipinmoroti AO; Crenshaw BJ; Pandit R; Kumar S; Sims B; Matthews QL
J Immunol Res; 2021; 2021():2958394. PubMed ID: 34926703
[TBL] [Abstract][Full Text] [Related]
13. Adenoviral Vector-Based Vaccine Platforms for Developing the Next Generation of Influenza Vaccines.
Sayedahmed EE; Elkashif A; Alhashimi M; Sambhara S; Mittal SK
Vaccines (Basel); 2020 Oct; 8(4):. PubMed ID: 33019589
[TBL] [Abstract][Full Text] [Related]
14. Applications of alginate microspheres in therapeutics delivery and cell culture: Past, present and future.
Dhamecha D; Movsas R; Sano U; Menon JU
Int J Pharm; 2019 Oct; 569():118627. PubMed ID: 31421199
[TBL] [Abstract][Full Text] [Related]
15. Biomaterial-Guided Gene Delivery for Musculoskeletal Tissue Repair.
Madrigal JL; Stilhano R; Silva EA
Tissue Eng Part B Rev; 2017 Aug; 23(4):347-361. PubMed ID: 28166711
[TBL] [Abstract][Full Text] [Related]
16. Evolving lessons on nanomaterial-coated viral vectors for local and systemic gene therapy.
Kasala D; Yoon AR; Hong J; Kim SW; Yun CO
Nanomedicine (Lond); 2016 Jul; 11(13):1689-713. PubMed ID: 27348247
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA delivery for regenerative medicine.
Peng B; Chen Y; Leong KW
Adv Drug Deliv Rev; 2015 Jul; 88():108-22. PubMed ID: 26024978
[TBL] [Abstract][Full Text] [Related]
18. Strategies to circumvent humoral immunity to adeno-associated viral vectors.
Tse LV; Moller-Tank S; Asokan A
Expert Opin Biol Ther; 2015 Jun; 15(6):845-55. PubMed ID: 25985812
[TBL] [Abstract][Full Text] [Related]
19. Adenovirus-triggered innate signalling pathways.
Fejer G; Freudenberg M; Greber UF; Gyory I
Eur J Microbiol Immunol (Bp); 2011 Dec; 1(4):279-88. PubMed ID: 24516734
[TBL] [Abstract][Full Text] [Related]
20. Hydrogels for lentiviral gene delivery.
Seidlits SK; Gower RM; Shepard JA; Shea LD
Expert Opin Drug Deliv; 2013 Apr; 10(4):499-509. PubMed ID: 23347508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
